Accelerate Diagnostics Net Long-Term Debt 2010-2024 | AXDX
Accelerate Diagnostics net long-term debt from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
| Accelerate Diagnostics Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $-1 |
| 2023 | $-1 |
| 2022 | $0 |
| 2021 | $0 |
| 2020 | $5 |
| 2019 | $N/A |
| 2018 | $167 |
| 2017 | $N/A |
| 2016 | $0 |
| 2015 | $0 |
| 2014 | $0 |
| 2013 | $N/A |
| 2012 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| 2010 | $N/A |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.013B | $0.012B |
| Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. | |||